文献速递皮肤肿瘤

microRNA液体活检用于侵袭性皮肤黑色素瘤诊断与风险分层的验证

Validation of a microRNA liquid biopsy assay for diagnosis and risk stratification of invasive cutaneous melanoma.
PubMed 文献 · Br J Dermatol · 2023-01-01

研究在多中心观察性病例对照研究中验证血浆microRNA标志物MEL38对侵袭性黑色素瘤的诊断效能,并开发预后标志物MEL12。MEL38评分>5.5提示侵袭性黑色素瘤,灵敏度93%、特异度98%,AUC 0.98。MEL12将患者分为低、标准、高风险组,10年黑色素瘤特异性生存率分别为94%、78%、58%。

要点

  • MEL38评分>5.5提示侵袭性黑色素瘤,灵敏度93%、特异度98%。
  • MEL38的AUC为0.98,95%CI 0.97-0.99,P<0.001。
  • MEL12高风险组前哨淋巴结检出黑色素瘤的可能性约为低风险组的3倍。

核心结论

  • 循环MEL38标志物可能有助于鉴别侵袭性黑色素瘤与死亡风险较低或可忽略的其他情况。
  • MEL12预后标志物可预测前哨淋巴结活检状态、临床分期和生存概率。

研究设计与样本

  • 多中心观察性病例对照研究,对血浆样本进行microRNA表达谱分析。
  • 共纳入372例侵袭性黑色素瘤患者和210例对照个体,平均年龄59岁,49%为男性。
  • 利用232例患者的microRNA谱开发预后标志物MEL12。

主要发现

  • MEL38评分>5.5提示侵袭性黑色素瘤,551/582(95%)患者被正确诊断,灵敏度93%,特异度98%。
  • MEL38评分范围0至10,AUC为0.98(95%CI 0.97-0.99,P<0.001)。
  • MEL12将患者分为低、标准、高风险组,10年黑色素瘤特异性生存率分别为94%、78%、58%(log-rank P<0.001)。
  • MEL12风险分组与临床分期(χ2,P<0.001)和前哨淋巴结活检状态(P=0.027)显著相关。
  • MEL12高风险组患者前哨淋巴结检出黑色素瘤的可能性约为低风险组的3倍。

关键数值与推荐

  • MEL38评分>5.5提示侵袭性黑色素瘤。
  • MEL38诊断灵敏度93%,特异度98%,AUC 0.98(95%CI 0.97-0.99,P<0.001)。
  • MEL12低、标准、高风险组10年黑色素瘤特异性生存率分别为94%、78%、58%(log-rank P<0.001)。

临床怎么用

  • 血浆microRNA谱可能有助于优化现有诊断路径。
  • MEL12可能有助于实现个体化、基于风险的黑色素瘤治疗决策。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Noninvasive molecular biomarkers are needed to improve the early, accurate and precise diagnosis of invasive cutaneous melanoma. OBJECTIVES: To independently validate a previously identified circulating microRNA signature of melanoma (MEL38), and, secondly, to develop a complementary microRNA signature, optimized for prognostication. PATIENTS AND METHODS: MicroRNA expression profiling was performed on plasma samples from a multicentre observational case-control study, involving patients with primary or metastatic melanoma, melanoma in situ, nonmelanoma skin cancer, or benign naevi. MicroRNA profiles from patients with length of survival, treatment and sentinel lymph node biopsy (SLNB) data were used to develop the prognostic signature. The primary outcome of interest for MEL38 was its association with melanoma status, including area under the curve, binary diagnostic sensitivity and specificity, and incidence-adjusted positive and negative predictive values. The prognostic signature was assessed using rates of survival per risk group and relationship to conventional predictors of outcome. RESULTS: Circulating microRNA profiles of 372 patients with invasive melanoma and 210 control individuals were generated. The average age of all participants was 59 years; 49% were male. A MEL38 score > 5.5 indicated the presence of invasive melanoma. Overall, 551/582 (95%) of patients were correctly diagnosed, with 93% sensitivity and 98% specificity. MEL38 score ranged from 0 to 10 with an area under the curve of 0.98 (95% confidence interval 0.97-0.99, P < 0.001). A novel prognostic 12-microRNA signature (MEL12) developed from 232 patients identified low-, standard- or high-risk groups, with 94%, 78% and 58% rates of 10-year melanoma-specific survival, respectively (log-rank P < 0.001). MEL12 prognostic risk groups were significantly associated with clinical staging (χ2, P < 0.001) and SLNB status (P = 0.027). Patients who were classified as high risk by MEL12 were approximately three times more likely to have melanoma detected in their sentinel lymph nodes compared to low-risk patients. CONCLUSIONS: The circulating MEL38 signature may assist in diagnosing patients with invasive melanoma vs. other conditions associated with a lower - or negligible - risk of mortality. A complementary and prognostic MEL12 signature is predictive of SLNB status, clinical stage and probability of survival. Plasma microRNA profiling may help to optimize existing diagnostic pathways as well as enable personalized, risk-informed melanoma treatment decisions.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Van Laar R, Latif B, King S, et al. Validation of a microRNA liquid biopsy assay for diagnosis and risk stratification of invasive cutaneous melanoma. Br J Dermatol. 2023. PMID: 37144735. doi:10.1093/bjd/ljad137

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。